Chromatin interactions and regulatory elements in cancer : from bench to bedside
Chromatin interactions regulate gene expression by bringing distal regulatory elements, such as super-enhancers, to promoters in close spatial proximity. It has been recognized that in cancer, chromatin interactions can be dysregulated, leading to aberrant oncogene expression. Chromatin interactions...
Saved in:
Main Authors: | , , |
---|---|
Other Authors: | |
Format: | Article |
Language: | English |
Published: |
2020
|
Subjects: | |
Online Access: | https://hdl.handle.net/10356/144387 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Nanyang Technological University |
Language: | English |
id |
sg-ntu-dr.10356-144387 |
---|---|
record_format |
dspace |
spelling |
sg-ntu-dr.10356-1443872023-02-28T16:57:19Z Chromatin interactions and regulatory elements in cancer : from bench to bedside See, Yi Xiang Wang, Benny Zhengjie Fullwood, Melissa Jane School of Biological Sciences Science::Biological sciences Chromatin Interactions Cancer Chromatin interactions regulate gene expression by bringing distal regulatory elements, such as super-enhancers, to promoters in close spatial proximity. It has been recognized that in cancer, chromatin interactions can be dysregulated, leading to aberrant oncogene expression. Chromatin interactions may potentially serve as biomarkers, or be modulated via CRISPR therapy and small molecule inhibitors against transcription. However, these methods face challenges that must be resolved and raise questions for further research. Understanding chromatin interactions is essential for safety aspects of anticancer therapies, such as the mechanism of action of epigenetic regulators and transcription factors in cancer, and potential off-target effects arising from targeting super-enhancers and promoters. In this review article, we discuss how chromatin interactions and regulatory elements may become dysregulated in cancer, potential methods to target them for clinical therapy, and outline outstanding questions that require addressing before epigenetic therapies can translate to the clinic safely and effectively. Ministry of Education (MOE) National Research Foundation (NRF) Accepted version This research is supported by the National Research Foundation (NRF) Singapore through an NRF Fellowship awarded to M.J.F (NRF-NRFF2012-054). This research is supported by the RNA Biology Center at the Cancer Science Institute of Singapore, NUS, as part of funding under the Singapore Ministry of Education Academic Research Fund Tier 3 (MOE2014- T3-1-006). This research is supported by the National Research Foundation Singapore and the Singapore Ministry of Education under its Research Centres of Excellence initiative. 2020-11-03T01:31:44Z 2020-11-03T01:31:44Z 2018 Journal Article See, Y. X., Wang, B. Z., & Fullwood, M. J. (2019). Chromatin interactions and regulatory elements in cancer : from bench to bedside. Trends in Genetics, 35(2), 145-158. doi:10.1016/j.tig.2018.11.007 0168-9525 https://hdl.handle.net/10356/144387 10.1016/j.tig.2018.11.007 2 35 145 158 en NRF-NRFF2012-054 MOE2014- T3-1-006 Trends in Genetics Trends in Genetics © 2018 Elsevier Ltd. All rights reserved. This paper was published in Trends in Genetics and is made available with permission of Elsevier Ltd. application/pdf application/pdf application/pdf application/pdf |
institution |
Nanyang Technological University |
building |
NTU Library |
continent |
Asia |
country |
Singapore Singapore |
content_provider |
NTU Library |
collection |
DR-NTU |
language |
English |
topic |
Science::Biological sciences Chromatin Interactions Cancer |
spellingShingle |
Science::Biological sciences Chromatin Interactions Cancer See, Yi Xiang Wang, Benny Zhengjie Fullwood, Melissa Jane Chromatin interactions and regulatory elements in cancer : from bench to bedside |
description |
Chromatin interactions regulate gene expression by bringing distal regulatory elements, such as super-enhancers, to promoters in close spatial proximity. It has been recognized that in cancer, chromatin interactions can be dysregulated, leading to aberrant oncogene expression. Chromatin interactions may potentially serve as biomarkers, or be modulated via CRISPR therapy and small molecule inhibitors against transcription. However, these methods face challenges that must be resolved and raise questions for further research. Understanding chromatin interactions is essential for safety aspects of anticancer therapies, such as the mechanism of action of epigenetic regulators and transcription factors in cancer, and potential off-target effects arising from targeting super-enhancers and promoters. In this review article, we discuss how chromatin interactions and regulatory elements may become dysregulated in cancer, potential methods to target them for clinical therapy, and outline outstanding questions that require addressing before epigenetic therapies can translate to the clinic safely and effectively. |
author2 |
School of Biological Sciences |
author_facet |
School of Biological Sciences See, Yi Xiang Wang, Benny Zhengjie Fullwood, Melissa Jane |
format |
Article |
author |
See, Yi Xiang Wang, Benny Zhengjie Fullwood, Melissa Jane |
author_sort |
See, Yi Xiang |
title |
Chromatin interactions and regulatory elements in cancer : from bench to bedside |
title_short |
Chromatin interactions and regulatory elements in cancer : from bench to bedside |
title_full |
Chromatin interactions and regulatory elements in cancer : from bench to bedside |
title_fullStr |
Chromatin interactions and regulatory elements in cancer : from bench to bedside |
title_full_unstemmed |
Chromatin interactions and regulatory elements in cancer : from bench to bedside |
title_sort |
chromatin interactions and regulatory elements in cancer : from bench to bedside |
publishDate |
2020 |
url |
https://hdl.handle.net/10356/144387 |
_version_ |
1759856045273907200 |